eureKARE co-leads EUR 5 million seed investment in Biomemory which is advancing cutting-edge DNA-based data storage solutions
Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology and IT and is a key player in the DNA data storage space. Its ambition is to help meet the climate challenge posed by data centers.
eureKARE launches innovation-driven start-up studio in Monaco to apply synthetic biology in tackling critical environmental challenges
This expands eureKARE’s synthetic biology studio network – each with a different theme – in Europe’s innovation hotspots. The Monaco studio will be the network’s hub for climate change-focused innovation.
When it comes to innovation in synthetic biology (or “SynBio”), we’re seeing Europe punch above its weight but there remains a disconnect in seeing this translate into commercial value and investment, falling behind other major players, namely the US.
[Translated in English from a tribune published in the French newspaper L’Opinion on October 27th 2022].
The health crisis has demonstrated with a brutality that has shocked – and sometimes bruised – many of our fellow citizens: Europe, and in particular France, has lost control of the supply chain of its health products, particularly of some of its Medicines of Major Therapeutic Interest (MMTI).
In his introductory speech, His Serene Highness Prince Albert II of Monaco stated: “I am especially pleased that the Principality of Monaco is able to welcome your work, support it and contribute to its success. I also welcome the dialogue that has been established between eureKARE and the Scientific Center of Monaco, in particular the opportunity to host one of your studios on its premises, like those you have already set up in various scientific centers across Europe”.
Organized by eureKARE and the Centre Scientifique de Monaco (CMS), SynBio Day, a conference about synthetic biology, took place in mid-October in the Principality of Monaco, giving an opportunity to discuss advances in technologies with tremendous potential.
Following the success of the inaugural 2021 event, SynBio Day 2022 will bring together researchers, industry partners, government representatives and investors to discuss the opportunities and challenges of applying synthetic biology solutions to tackle climate change and benefit our environment.
eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium.
Georges Rawadi appointed eureKARE’s Chief of Biotech Studio Development.
eureKARE supports eureKING in EUR 150 million listing of the first European healthcare SPAC dedicated to biomanufacturing
eureKARE announces the successful IPO on Euronext Paris of eureKING, the first European SPAC1 in healthcare dedicated to biomanufacturing that has been co-founded by eureKARE.
This collaboration aims to complete NovoBiome’s disruptive NovoSift® ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.